Pre-clinical studies in mouse models of inflammatory arthritis strongly suggest that agents that interfere with certain steps of glycolysis can be therapeutic in RA and have identified potential targetable glycolytic enzymes such as HK2, and glycolytic intermediate metabolites (Table 1). The gene discussed is HK2; the disease is rheumatoid arthritis.